NCT06010862View on ClinicalTrials.gov

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions
Gastric CancerColon CancerPancreas CancerEsophagus CancerCholangiocarcinomaLung CancerBreast Cancer
Interventions
BIOLOGICAL

CEA CAR-T cells

After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically

BIOLOGICAL

CEA CAR-T cells

After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
collaborator

The First Affiliated Hospital of Nanchang University

OTHER

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY